Investigational drug · Phase 2
GW906
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Hypertension.
Phase 2Last checked: Nov 19, 2026Latest source record: Sep 23, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
4
Any phase or sponsor naming "GW906"
First trial start
2025
Dec 24, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "GW906", any sponsor or status.
Conditions studied
As listed on its trial records.
- Hypertension
Approved drugs for the same conditions: High blood pressure (hypertension) · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "GW906" as an intervention, largest first.
Shenzhen Salubris Pharmaceuticals Co., Ltd.Industry
NCT07879755 · 1,500 participants (planned) · Start Jun 12, 2026 · Primary completion Jan 30, 2029
Drug: GW906 · For: Hypertension
Sites: Shanghai, China
- A Study to Evaluate Efficacy and Safety of GW906 Used as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by One or Two Antihypertensive MedicationsPivotal-lookingNot yet recruiting
Shenzhen Salubris Pharmaceuticals Co., Ltd.Industry
NCT07835984 · 560 participants (planned) · Start Oct 2026 · Primary completion Oct 2027
Drug: GW906; Placebo · For: Hypertension
Sites: Hangzhou, China
- A Study to Evaluate Efficacy and Safety of GW906 in Patients With Essential HypertensionPivotal-lookingActive, not recruiting
Shenzhen Salubris Pharmaceuticals Co., Ltd.Industry
NCT07835971 · 319 participants · Start Dec 24, 2025 · Primary completion Sep 15, 2026
Drug: GW906; Placebo · For: Hypertension
Sites: Shanghai, China
Shenzhen Salubris Pharmaceuticals Co., Ltd.Industry
NCT07884461 · 40 participants · Start Mar 29, 2025 · Primary completion Aug 24, 2026
Drug: GW906 injection; Placebo · For: Hypertension
Sites: Beijing, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Hypertension
- CagrilintidePhase 320 trials
Novo Nordisk · Obesity, Overweight, Type 2 Diabetes
- CagriSemaCagrilintide B and Semaglutide IPhase 36 trials
Novo Nordisk · Obesity, Diabetes Mellitus, Type 2, Hypertension
- lorundrostatPhase 35 trials
Mineralys Therapeutics Inc. · Hypertension, Obstructive Sleep Apnea, Chronic Kidney Disease
- VCT220CX11Phase 35 trials
Vincentage Pharma Co., Ltd · Obesity, Type 2 Diabetes Mellitus (DM), Hypertension
- VicadrostatBI 690517Phase 35 trials
Boehringer Ingelheim · Heart Failure, Diabetes Mellitus, Type 2, Hypertension
- ZilebesiranALN-AGT01Phase 34 trials
Alnylam Pharmaceuticals · Hypertension, High Cardiovascular Risk, High Risk Cardiovascular Disease
- ClazakizumabLY5724886, CSL300Phase 32 trials
Eli Lilly · Atherosclerosis, Cardiovascular Disease, Obesity
- DWC202314Phase 32 trials
Daewoong Pharmaceutical Co. LTD. · Essential Hypertension, Hypertension
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.